Jens Vogel Archives - Executive Platforms: Thought Leader Series

Towards Industrialization of Cell Therapy

November 22, 2023

This discussion will focus on the scientific, technical and cultural transformations required to drive towards true industrialization of cell therapies, including: — Jens VogelSVP & Global Head of BiotechBayer Pharmaceuticals Dr. Jens Vogel is SVP & Global Head of Biotech, Bayer Pharmaceuticals Product Supply, leading biologics operations, development and strategy across five sites, including cell & gene therapy industrialization. Jens has more than 20 years of professional and leadership experience in biologics development, operations, program management and regulatory affairs. Before rejoining Bayer in March 2020, he was President and CEO of Boehringer Ingelheim Fremont and member of BI’s Biopharma Executive…

Transforming a Global Development & Product Supply Network for Delivering a Multi-Modal Portfolio – It’s More than Flexible Facilities

May 26, 2023

Re-designing your organization to leverage capabilities across modalities In agile ways Designing technology platforms as you design products Laying the foundation for change during a pandemic builds flexibility and resilience in employees, setting the course for new ways of working and breaking down silos Strengthening a culture of inclusion and driving diversity in leadership ranks — Jens Vogel SVP & Global Head of Biotech Bayer Pharmaceuticals Dr. Jens Vogel rejoined Bayer in March of 2020 as Global Head of Biotech for the Bayer Pharmaceuticals Product Supply organization. He has more than 20 years of professional and leadership experience in the…

Towards Industrialization of Cell Therapy

November 23, 2022

Cell therapy, such as regenerative therapies based on iPSCs and adoptive cell therapies targeting cancer with CAR-T cells, CAR-NKs or TCRs hold enormous potential for the future of medicine, enabling for the first time curative approaches. However, the field is still in its infancy and CMC remains a critical bottleneck in bringing these therapies to patients on a global scale. This discussion will focus on the scientific, technical and cultural transformations required to drive towards true industrialization of cell therapies, including: The critical challenges in CMC for cell therapies today How more in-depth understanding of cells, their critical quality attributes…

7 Comments

LIFE SCIENCES, LIFE SCIENCES, VIDEO

The Future of Biomanufacturing: Leveraging Flexible Networks, Quality Culture and Cutting Edge Innovation

January 10, 2020

How biomanufacturing can address the dichotomy of small volume precision medicines and high volume blockbuster drugs Building flexible global manufacturing networks to meet our industry’s evolving needs Leveraging cutting edge innovation to maximize process intensification and augment flexibility Creating high performance teams and building and maintaining a culture of quality, reliability and innovation as key differentiator and foundation for continued success Please note: Q&A appears in this separate video: — Jens Vogel President & CEO, BI Fremont Inc. Boehringer Ingelheim Biopharmaceuticals GmbH Dr. Jens Vogel is President and CEO of Boehringer Ingelheim Fremont Inc., the US arm of Boehringer…

Jens Vogel

Towards Industrialization of Cell Therapy

Towards Industrialization of Cell Therapy

The Future of Biomanufacturing: Leveraging Flexible Networks, Quality Culture and Cutting Edge Innovation

NASCES

NAFS

NAFMS

EUSCES

BMWS

NAFES

NASRS

NAMES

PMWS

NAISS

NAHRES

Categories

Newsletter